

## **Implantica publishes Year-end Report, January – December 2023 (Q4)**

### **REFLUXSTOP™ – GAINING SPEED, BREAKING BOUNDARIES AND GOING GLOBAL**

#### **Significant events in the fourth quarter of 2023**

- Selected U.S. surgeons begin the standardized RefluxStop™ surgery training program
  - in preparation for Cadaver Usability study during Q1 2024
  - from over 10 key centers in U.S.
  - results to be used in our PMA application to FDA
- Successful 2nd Annual RefluxStop™ Users Meeting
  - > 50 participants attended
  - surgeons and GIs from U.S., Canada, U.K. and across Europe
- RefluxStop™ cost-effectiveness research received top recognition at ISPOR, leading European health-economics conference
  - key finding: RefluxStop™ more cost-effective than the competition
  - economic analyses for 4 additional countries completed
- RefluxStop™ prominently featured at Annual European Foregut Society (EFS) congress in Milan
  - successful symposium on RefluxStop™ by 8 leading GERD surgeons & GIs from Austria, Germany, Switzerland, Italy, U.K. and U.S.

#### **Significant events after the end of the period**

- First-ever public tender win for RefluxStop™ achieved by Ospedale di Moncalieri Turin, Italy
  - 3-year public tender
  - hospital to be funded full list price by public healthcare system
- Added 9 new leading reflux centers since beginning of Q4
  - 25 RefluxStop™ centers in our target markets in Europe at the beginning of the year
  - >650 patients successfully operated in Europe
- Live RefluxStop™ surgery performed at the 34th Congress of Digestive System Surgery in Rome
  - nearly 2,000 surgeons attended
  - streamed by up to 100,000 online, nearly 90,000 international viewers
- Two new key clinical and health-economics peer-reviewed papers published during Q4
  - health-economics paper, budget impact analysis of RefluxStop™ in U.K.
  - clinical paper, RefluxStop™ results in large hiatal hernia patients

#### **Fourth quarter financial summary**

- Net sales increased 110% to TEUR 508 (242).
- Adjusted gross margin amounted to 92% (96%).
- Operating loss (EBIT) increased to TEUR 6,942 (5,108).
- Loss after tax amounted to TEUR 8,734 (4,747).
- Basic and diluted loss per Class A share amounted to EUR 0.12 (0.07).
- Cash as at the end of the period amounted to MEUR 87.9.

### Full year financial summary

- Net sales increased 67% to TEUR 1,408 (842).
- Adjusted gross margin amounted to 94% (96%).
- Operating loss (EBIT) increased to TEUR 21,840 (18,447).
- Loss after tax amounted to TEUR 24,502 (21,361).
- Basic and diluted loss per Class A share amounted to EUR 0.34 (0.30).

### Telephone conference

Implantica will hold a teleconference on 16 February 2024 at 15:00 (CET) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer).

Please see the dial-in details below to join the conference:

Webcast:

<https://ir.financialhearings.com/implantica-q4-2023>

Dial-in:

numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference

<https://conference.financialhearings.com/teleconference/?id=5002461>

### For further information, please contact:

Nicole Pehrsson, Chief Corporate Affairs Officer

Telephone (CH): +41 (0)79 335 09 49

[nicole.pehrsson@implantica.com](mailto:nicole.pehrsson@implantica.com)

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, [info@fnca.se](mailto:info@fnca.se)

*This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-16 08:00 CET.*

### About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit [www.implantica.com](http://www.implantica.com) for further information.